Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.41 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23637703 | 0.85 | MAPK14 (0.59) | CYP17A1MAPK14MAPK13NR3C2 | |
| SCHEMBL2858354 | 0.81 | MAPK14 (0.63) | CYP17A1MAPK14MAPK13 | |
| SCHEMBL16245955 | 0.81 | CYP17A1 (0.48) | CYP17A1MAPK14KCNQ4KCNQ5 | |
| SCHEMBL16246161 | 0.80 | CYP17A1 (0.47) | CYP17A1MAPK14KCNQ4KCNQ5 | |
| SCHEMBL29468015 | 0.80 | CYP17A1 (0.49) | CYP17A1KCNQ4KCNQ5AAK1 | |
| SCHEMBL28207323 | 0.78 | CYP17A1 (0.50) | CYP17A1MAPK14KCNQ4KCNQ5AAK1 | |
| SCHEMBL3832059 | 0.77 | KCNQ4 (0.50) | CYP17A1KCNQ4KCNQ5AAK1 | |
| SCHEMBL23201680 | 0.77 | MAPK14 (0.78) | MAPK14MAPK13 | |
| SCHEMBL23201664 | 0.77 | MAPK14 (0.77) | MAPK14MAPK13 | |
| SCHEMBL1137136 | 0.76 | CYP17A1 (0.47) | CYP17A1MAPK14AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219489-A2 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Washington University (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | CYP17A1 2411/4885MAPK14 4/4885MAPK13 1/4885 |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | CYP17A1 2411/4885MAPK14 4/4885MAPK13 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.